NCT06888115View on ClinicalTrials.gov

A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

May 29, 2025

Study Completion Date

June 3, 2025

Conditions
Primary Biliary Cholangitis
Interventions
DRUG

CS0159

Single oral dose of CS0159 4mg

Trial Locations (3)

200000

Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

215000

The First Affiliated Hospital of Soochow University, Suzhou

The Second Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Cascade Pharmaceuticals, Inc

OTHER

NCT06888115 - A Study of the Pharmacokinetics and Safety of CS0159 in Subjects With Hepatic Injury | Biotech Hunter | Biotech Hunter